153559-76-3

153559-76-3 structure

Name: LG100268
Chemical Name: 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
CAS Number: 153559-76-3
Molecular Formula: C₂₄H₂₉NO₂
Molecular Weight: 363.49300
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2018-12-02 14:47:24
Modify Date: 2024-01-05 17:09:28
LG100268 (LG268) is a potent, selective and orally active retinoid X receptor (RXR) agonist with EC50 values of 4 nM, 3 nM, and 4 nM for RXR-α, RXR-β, and RXR-γ, respectively[1]. LG100268 displays >1000-fold selectivity for RXR over RAR, the Ki values are 3.4 nM, 6.2 nM and 9.2 nM for RXR-α, RXR-β, and RXR-γ, respectively[2]. LG100268 activates RXR homodimers to induce transcriptional activation. LG100268 can be used for the study of lung carcinogenesisy[3].

Name	6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
Synonyms	AmbkkkkK580 BIDD:PXR0022

Description	LG100268 (LG268) is a potent, selective and orally active retinoid X receptor (RXR) agonist with EC50 values of 4 nM, 3 nM, and 4 nM for RXR-α, RXR-β, and RXR-γ, respectively[1]. LG100268 displays >1000-fold selectivity for RXR over RAR, the Ki values are 3.4 nM, 6.2 nM and 9.2 nM for RXR-α, RXR-β, and RXR-γ, respectively[2]. LG100268 activates RXR homodimers to induce transcriptional activation. LG100268 can be used for the study of lung carcinogenesisy[3].
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Metabolic Disease Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR
In Vitro	LG100268 (100 nM-1 μM; 24 hours) shows a downregulation of CSF3 and a 2.5-fold decrease of CXCL2 and IL-1β mRNA expression in RAW264.7 cells[3]. Cell Viability Assay[3] Cell Line: RAW264.7 cells Concentration: 100 nM-1 μM Incubation Time: 24 hours Result: Decreased LPS induced cytokine mRNA levels.
In Vivo	LG100268 (oral diet; 100 mg/kg; once daily; 7 weeks) combines with C/P presents a more markedly reduced average tumor burden than LG268 or C/P alone. The combination establish a reduced lung tumors, which represents a reduction of 82% (vs. 59%-67% with the single drugs) in comparison with the controls[3]. Animal Model: A/J mice[3] Dosage: 50 mg/kg (Combines with carboplatin (50 mg/kg i.p.) starts 1 week after the LG268 treatment diet) Administration: Oral diet; once daily; 7 weeks Result: Decreased lung tumors growth significantly in mice.
References	[1]. M F Boehm, et al. Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells. J Med Chem [2]. D S Lala, et al. Activation of Specific RXR Heterodimers by an Antagonist of RXR Homodimers.Nature. 1996 Oct 3;383(6599):450-3. [3]. Martine Cao,et al.The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice. Cancer Prev Res (Phila). 2016 Jan;9(1):105-14.

Density	1.115g/cm3
Boiling Point	487ºC at 760mmHg
Melting Point	275-277ºC
Molecular Formula	C₂₄H₂₉NO₂
Molecular Weight	363.49300
Flash Point	248.3ºC
Exact Mass	363.22000
PSA	50.19000
LogP	5.51710
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.577
Storage condition	-20°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: US5921500

CHEMICAL NAME :: 3-Pyridinecarboxylic acid, 6-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naph thalenyl) cyclopropyl)-

CAS REGISTRY NUMBER :: 153559-76-3

LAST UPDATED :: 199806

DATA ITEMS CITED :: 1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 21780 ug/kg/3D-I

TOXIC EFFECTS :: Liver - other changes Biochemical - Effect on specific coenzyme - CoA

REFERENCE :: FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1981- Volume(issue)/page/year: 33,264,1996

RIDADR	NONH for all modes of transport

1158522-08-7	940364-43-2
134104-43-1	131615-57-1
2309774-31-8	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1